Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083454 | 0.84 | L3MBTL1 (0.36) | ALDH1A1LMNATSHRMAPTZDHHC20 | |
| SCHEMBL9360783 | 0.80 | ADRA2A (0.37) | ALDH1A1TSHRMAPTZDHHC20ZDHHC2 | |
| SCHEMBL7003693 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNATSHRMAPT | |
| SCHEMBL15083614 | 0.79 | — | — | |
| SCHEMBL15083603 | 0.79 | CA12 (0.35) | ALDH1A1LMNA | |
| SCHEMBL5439764 | 0.78 | ALDH1A1 (0.43) | ALDH1A1LMNATSHRABCC4MAPT | |
| SCHEMBL5712605 | 0.77 | — | — | |
| SCHEMBL11330333 | 0.76 | ALDH1A1 (0.42) | ALDH1A1LMNATSHRABCC4MAPT | |
| SCHEMBL734227 | 0.76 | ALDH1A1 (0.38) | ALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL3316103 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20170200973-A1 | ELECTROLYTIC SOLUTION, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9608289-B2 | Electrolytic solution, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic apparatus | SONY CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-7824899-B2 | Preparation of enantiomerically enriched amines and amides by enzymatic resolution using a sulfonylacetic acid ester as acyl donor | EVONIK DEGUSSA GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1870475-B1 | Process for the preparation of optically active amines and amides employing a hydrolase and sulfonyl acetic acid ester as the acyl donor | EVONIK DEGUSSA GMBH (DE) | 2008-12-10 | — | — | EP | disclosed |
| US-20070298471-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED AMINES AND AMIDES BY ENZYMATIC RESOLUTION | DEGUSSA GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1870475-A1 | Process for the preparation of optically active amines and amides employing a hydrolase and sulfonyl acetic acid ester as the acyl donor | Evonik Degussa GmbH (DE) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885LMNA 2193/4885TSHR 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.